Credit Suisse Affirms Positive View on Zoetis (ZTS) Amid CFO Transition; Retains 'Outperform' Rating
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Guggenheim Remains Positive on Zoetis (ZTS) as CFO Departs for Valeant (VRX)
August 22, 2016 11:16 AM EDTGuggenheim is out with commentary on recent CFO changes at Zoetis (NYSE: ZTS) and Valeant. The firm rates Zoetis at Buy with a price target of $60.
Analyst Louise Chen comemnted, In Specialty Pharma it seems as if conservation of mass applies to senior leadership changes within the industry. Yesterday evening, Zoetis announced... More
Valeant hires Zoetis's Paul Herendeen as CFO
August 22, 2016 6:14 AM EDT(Reuters) - Valeant Pharmaceuticals International Inc (NYSE: VRX) named Zoetis Inc (NYSE: ZTS) executive Paul Herendeen as its chief financial officer, replacing Robert Rosiello, the latest in a series of management changes at the Canadian drugmaker.
... MoreZoetis (ZTS) Names New CFO
August 22, 2016 6:07 AM EDTZoetis Inc. (NYSE: ZTS) announced that Glenn David, Senior Vice President of Finance Operations, has been named Executive Vice President and Chief Financial Officer (CFO), and will assume responsibility for the oversight of the companys financial management, planning and global operations, effective immediately. As CFO, David will report directly to Chief Executive Officer... More
Valeant Pharma (VRX) Names Paul Herendeen as CFO
August 22, 2016 6:04 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that Paul S. Herendeen has been appointed Executive Vice President, Finance and will take over the role of Chief Financial Officer from Robert L. Rosiello effective immediately. Mr. Rosiello will remain at Valeant as Executive Vice President, Corporate Development and Strategy.
Mr. Herendeen has more than 30 years of broad financial experience and leadership, including 16 years as CFO of Warner Chilcott and MedPointe. He joins Valeant from Zoetis (NYSE: ZTS), where he served as Executive Vice President... More
